Browse the evidence

Rifampicin inhibits body weight gain in high-fat diet-fed mice.

Rifampicin may be considered as a potential treatment for obesity in high-fat diet contexts.

Rifampicin enhances lipolysis and suppresses lipogenesis in adipocytes.

Rifampicin may be useful in promoting fat loss by altering lipid metabolism.

The effects of rifampicin on obesity are mediated through Sirt6.

Targeting Sirt6 may enhance the effectiveness of rifampicin in obesity treatment.

Novel drug candidates like dual amylin and calcitonin receptor agonists (DACRAs) have insulin-sensitizing properties through a weight-independent action.

DACRAs may offer new treatment options for improving insulin sensitivity.

Mice receiving NN501 display a more gradual weight regain and no compensatory hyperphagic response after treatment cessation.

NN501 may help in maintaining weight loss without the rebound effects seen with other treatments.

GLP-1 receptor agonists (GLP-1RAs) may have neuroprotective and neurotrophic effects in ALS models.

GLP-1RAs may be considered for further investigation in ALS treatment.

Current clinical evidence does not demonstrate therapeutic benefit of GLP-1RAs in ALS.

Clinicians should be cautious in prescribing GLP-1RAs for ALS due to lack of evidence.

Obesity is characterized by adipose tissue dysfunction, insulin resistance, chronic low-grade inflammation, and gut microbiota dysbiosis.

Understanding these characteristics can help in developing targeted interventions for obesity.

Prior GLP-1 agonist use is not associated with in-hospital mortality in critically ill patients.

Clinicians may consider that prior GLP-1 agonist use does not adversely affect mortality in critically ill patients.

Prior GLP-1 agonist use is not associated with hospital length of stay in critically ill patients.

Clinicians may conclude that prior GLP-1 agonist use does not prolong hospital stays for critically ill patients.

Prior GLP-1 agonist use is not associated with ICU length of stay in critically ill patients.

Clinicians may determine that prior GLP-1 agonist use does not affect ICU length of stay for critically ill patients.

Greater achieved weight loss during the landmark period did not show a consistent association with lower post-landmark cardiovascular risk.

Weight loss alone may not be sufficient to reduce cardiovascular risk, emphasizing the importance of medication dosage.

Women's adjusted odds of diagnosis were far higher than men's (95% confidence interval 1.66-1.75).

Healthcare providers should consider gender disparities in obesity diagnosis when assessing patients.

Liraglutide did not have measurable effects on lean or bone tissue over the 18-day period.

Liraglutide may not affect muscle or bone mass in the short term.

Obesity is defined as a BMI of more than 30 kg/m2 and is a prevalent chronic disease.

Healthcare practitioners should recognize obesity as a significant health challenge.

The incidence of obesity has nearly trebled since 1975.

Public health initiatives must address the rising rates of obesity.

The comparative bioavailability of semaglutide following oral administration (3 mg) relative to subcutaneous administration (0.25 mg) is 0.66%.

Practitioners should note the lower bioavailability of oral semaglutide compared to subcutaneous administration.

The pharmacokinetics of semaglutide was characterized following the administration of low subcutaneous and oral doses.

Understanding the pharmacokinetics can inform dosing strategies for semaglutide.

The study drug was well tolerated, and no serious adverse events were reported.

Practitioners can consider semaglutide safe for use in healthy individuals based on this study.

There were no reports of pharmacotherapies for weight management in the studies reviewed.

Practitioners should be aware that pharmacotherapy options are not currently reported for this population.

Research is being pursued to investigate glucose-lowering agents for their anti-inflammatory, neuroprotective, and lipotoxic reduction effects.

Future research may expand the therapeutic applications of these medications.

Obstacles in integrating injectables into existing regimens include restricted access to information and insufficient training.

Training and access to information are crucial for effective diabetes management.

SGLT-2 inhibitors lower blood sugar independently of insulin, reduce heart failure risk, slow kidney disease progression, and possess senolytic properties.

SGLT-2 inhibitors may be beneficial for patients with diabetes and related complications.

Molecular engineering strategies have advanced biologic therapies for diabetes by optimizing therapeutic stability, pharmacokinetics, and delivery.

Practitioners can leverage molecular engineering to enhance diabetes therapies.